These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33961310)

  • 1. A phase Ib/IIa, open-label, multiple ascending-dose trial of domagrozumab in fukutin-related protein limb-girdle muscular dystrophy.
    Leung DG; Bocchieri AE; Ahlawat S; Jacobs MA; Parekh VS; Braverman V; Summerton K; Mansour J; Stinson N; Bibat G; Morris C; Marraffino S; Wagner KR
    Muscle Nerve; 2021 Aug; 64(2):172-179. PubMed ID: 33961310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal functional and imaging outcome measures in FKRP limb-girdle muscular dystrophy.
    Leung DG; Bocchieri AE; Ahlawat S; Jacobs MA; Parekh VS; Braverman V; Summerton K; Mansour J; Bibat G; Morris C; Marraffino S; Wagner KR
    BMC Neurol; 2020 May; 20(1):196. PubMed ID: 32429923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy.
    Wagner KR; Abdel-Hamid HZ; Mah JK; Campbell C; Guglieri M; Muntoni F; Takeshima Y; McDonald CM; Kostera-Pruszczyk A; Karachunski P; Butterfield RJ; Mercuri E; Fiorillo C; Bertini ES; Tian C; Statland J; Sadosky AB; Purohit VS; Sherlock SP; Palmer JP; Binks M; Charnas L; Marraffino S; Wong BL
    Neuromuscul Disord; 2020 Jun; 30(6):492-502. PubMed ID: 32522498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathies.
    Serafini PR; Feyder MJ; Hightower RM; Garcia-Perez D; Vieira NM; Lek A; Gibbs DE; Moukha-Chafiq O; Augelli-Szafran CE; Kawahara G; Widrick JJ; Kunkel LM; Alexander MS
    JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C.
    Bogdanovich S; McNally EM; Khurana TS
    Muscle Nerve; 2008 Mar; 37(3):308-16. PubMed ID: 18041051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Childhood Activity on Progression in Limb Girdle Muscular Dystrophy 2I.
    Brun BN; Mockler SR; Laubscher KM; Stephan CM; Collison JA; Zimmerman MB; Mathews KD
    J Child Neurol; 2017 Feb; 32(2):204-209. PubMed ID: 27872178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sexually dimorphic skeletal muscle and cardiac dysfunction in a mouse model of limb girdle muscular dystrophy 2i.
    Maricelli JW; Kagel DR; Bishaw YM; Nelson OL; Lin DC; Rodgers BD
    J Appl Physiol (1985); 2017 Nov; 123(5):1126-1138. PubMed ID: 28663375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF-06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects.
    Bhattacharya I; Pawlak S; Marraffino S; Christensen J; Sherlock SP; Alvey C; Morris C; Arkin S; Binks M
    Clin Pharmacol Drug Dev; 2018 Jun; 7(5):484-497. PubMed ID: 28881472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Open Label Exploratory Clinical Trial Evaluating Safety and Tolerability of Once-Weekly Prednisone in Becker and Limb-Girdle Muscular Dystrophy.
    Zelikovich AS; Joslin BC; Casey P; McNally EM; Ajroud-Driss S
    J Neuromuscul Dis; 2022; 9(2):275-287. PubMed ID: 35124660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contractile properties are disrupted in Becker muscular dystrophy, but not in limb girdle type 2I.
    Løkken N; Hedermann G; Thomsen C; Vissing J
    Ann Neurol; 2016 Sep; 80(3):466-71. PubMed ID: 27463532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global FKRP Registry: observations in more than 300 patients with Limb Girdle Muscular Dystrophy R9.
    Murphy LB; Schreiber-Katz O; Rafferty K; Robertson A; Topf A; Willis TA; Heidemann M; Thiele S; Bindoff L; Laurent JP; Lochmüller H; Mathews K; Mitchell C; Stevenson JH; Vissing J; Woods L; Walter MC; Straub V
    Ann Clin Transl Neurol; 2020 May; 7(5):757-766. PubMed ID: 32342672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal muscle contractile properties in a novel murine model for limb girdle muscular dystrophy 2i.
    Rehwaldt JD; Rodgers BD; Lin DC
    J Appl Physiol (1985); 2017 Dec; 123(6):1698-1707. PubMed ID: 28860175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two siblings with limb-girdle muscular dystrophy type 2E responsive to deflazacort.
    Wong-Kisiel LC; Kuntz NL
    Neuromuscul Disord; 2010 Feb; 20(2):122-4. PubMed ID: 20071171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient engraftment of pluripotent stem cell-derived myogenic progenitors in a novel immunodeficient mouse model of limb girdle muscular dystrophy 2I.
    Azzag K; Ortiz-Cordero C; Oliveira NAJ; Magli A; Selvaraj S; Tungtur S; Upchurch W; Iaizzo PA; Lu QL; Perlingeiro RCR
    Skelet Muscle; 2020 Apr; 10(1):10. PubMed ID: 32321586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Limb-Girdle Muscular Dystrophy type R9 linked to the FKRP gene: state of the art and therapeutic perspectives].
    Villar Quiles RN; Richard I; Bouchet-Seraphin C; Stojkovic T
    Med Sci (Paris); 2020 Dec; 36 Hors série n° 2():28-33. PubMed ID: 33427633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic Resonance Imaging Findings in the Muscle Tissue of Patients with Limb Girdle Muscular Dystrophy Type 2I Harboring the Founder Mutation c.545A>G in the
    Xie Z; Xiao J; Zheng Y; Wang Z; Yuan Y
    Biomed Res Int; 2018; 2018():3710814. PubMed ID: 30003095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy.
    Wojciechowski J; Purohit VS; Harnisch LO; Dua P; Tan B; Nicholas T
    Clin Pharmacol Ther; 2022 Dec; 112(6):1291-1302. PubMed ID: 36104012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of limb girdle muscular dystrophy R9 over 6 years: searching for trial endpoints.
    Murphy AP; Morrow J; Dahlqvist JR; Stojkovic T; Willis TA; Sinclair CDJ; Wastling S; Yousry T; Hanna MS; James MK; Mayhew A; Eagle M; Lee LE; Hogrel JY; Carlier PG; Thornton JS; Vissing J; Hollingsworth KG; Straub V
    Ann Clin Transl Neurol; 2019 Jun; 6(6):1033-1045. PubMed ID: 31211167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I.
    Frattini P; Villa C; De Santis F; Meregalli M; Belicchi M; Erratico S; Bella P; Raimondi MT; Lu Q; Torrente Y
    Hum Mol Genet; 2017 Oct; 26(19):3682-3698. PubMed ID: 28666318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.